AC Immune S.A. is a biotechnology company focused on developing therapies and diagnostics for neurodegenerative diseases, particularly Alzheimer's disease and other proteinopathies
The company utilizes its innovative approach to identify and target misfolded proteins that are implicated in these conditions. By leveraging advanced technology platforms, AC Immune is engaged in the discovery and development of disease-modifying treatments and biomarkers, aiming to address significant unmet medical needs in the field of neurology and enhance the understanding of these complex diseases.
AC Immune SA (NASDAQACIU) shares surged Tuesday after the company received FDA Fast Track Designation for its anti-amyloid-beta active immunotherapy, ACI-24.060,
Unlocking hope for Alzheimer's with ACI-24.060. Takeda's agreement with AC Immune targets toxic forms of Abeta, potentially slowing disease progression.
AC Immune SA's (NASDAQACIU) development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with...
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this
